Alexey S. Kalpinskiy

Alexey S. Kalpinskiy

Auto-generated profile, based on publicly available information

Alexey S. Kalpinskiy

P. A. Hertsen Moscow Oncology Research Institute — branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Biochimie
Verified
Journal Article
Closed access
ABAlexey Baldin
Alexey Baldin
AGAlena N. Grishina
Alena N. Grishina
DKDmitry O. Korolev
Dmitry O. Korolev
EKEkaterina B. Kuznetsova
Ekaterina B. Kuznetsova
MGMarina O. Golovastova
Marina O. Golovastova
Andrey A. Zamyatnin Jr.Andrey A. Zamyatnin Jr.
Andrey A. Zamyatnin Jr.

30 December 2016 in Cancer Urology
Verified
Journal Article
Open access
PDF file
BAB. Ya. Alekseev
B. Ya. Alekseev
KNK. M. Nyushko
K. M. Nyushko
SRS. A. Reva
S. A. Reva
AНArray К. Носов
Array К. Носов
DPD. G. Prokhorov
D. G. Prokhorov
AШArray И. Школьник
Array И. Школьник
Prostate cancer (PC) is one of the most challenging and pressing problems of modern oncourology because of high morbidity associated with the disease. The main methods of radical treatment of patients with localized and regional PC are radical prostatectomy and beam radiation therapy, external or brachytherapy. Nonetheless, the rate of biochemical progression of the disease after radical treatment remains high and averages 27–53 %. Of the utmost importance is determination of the tumor nidus which raises the marker level. Currently, in patients with distant metastases the only widely accepted treatment method is palliative hormonal therapy (HT). However, in majority of patients marker recurrence can be associated with so-called oligometastatic progression characterized by a minimal number of detectable metastases. Research shows that surgical treatment or beam radiation therapy in selected patients of this cohort allows to significantly increase the time until HT prescription, and in some cases to abandon it altogether. The article describes the results of surgical treatment of patients subjected to salvage lymphadenectomy for oligometastatic PC progression at three centers: P.A. Hertzen Moscow Oncology Research Institute, N.N. Petrov Research Institute of Oncology and Russian Research Center for Radiology and Surgical Technologies. In the multicenter study, short-term and longterm results of surgical treatment of 57 patients were evaluated. It was shown that in some patients, salvage lymphadenectomy can be an effective treatment option significantly lengthening the time until HT prescription, and in 23.4 % of patients it can lead to long-term (12 months) stabilization of the disease and 90 % decrease in prostate-specific antigen level compared to the initial pre-surgery level without any additional forms of therapy.

30 June 2017 in Cancer Urology
Verified
Journal Article
Open access
PDF file
BAB. Ya. Alekseev
B. Ya. Alekseev
AKA. S. Kalpinskiy
A. S. Kalpinskiy
AMA. A. Mukhomed’yArova
A. A. Mukhomed’yArova
KNK. M. Nyushko
K. M. Nyushko
AKA. D. Kaprin
A. D. Kaprin
The majority of patients with metastatic renal cell carcinoma (mRCC) are in the groups of favorable or moderate prognosis per the MSKCC (MemorialSloan-KetteringCancerCenter) criteria, but in 20–30 % of poor-prognosis patients aggressive, rapidly progressing mRCC is observed. Despite improved prognosis in mRCC patients due to targeted therapy, this patient group remains hard to treat with overall survival 6 months) was higher in the temsirolimus (32.1 %) and combination (28.1 %) groups compared to the IFN-α group (15.5 %; р0,001).

24 March 2016 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
ESE. U. Safronova
E. U. Safronova
KNK. M. Nushko
K. M. Nushko
BAB. Y. Alekseev
B. Y. Alekseev
AKA. S. Kalpinskiy
A. S. Kalpinskiy
VPV. A. Polyakov
V. A. Polyakov
AKA. D. Kaprin
A. D. Kaprin
Почечно-клеточный рак является актуальной проблемой в онкоурологической практике. Широкое использование методов лучевой диагностики увеличило частоту выявления локализованных опухолей небольших размеров, что привело к росту количества пациентов, которым показано выполнение органосохраняющих хирургических вмешательств. Резекция почки является эффективным, относительно безопасным и наиболее часто используемым методом терапии у данного контингента больных. В то же время, выполнение резекции почки связано с необходимостью осуществления гемостаза при операциях на активно васкуляризированном органе. Таким образом, адекватный гемостаз является наиболее важным этапом операции при выполнении резекции почки. Методики, направленные на осуществление гемостаза разнообразны и включают различные способы механического, физического и химического воздействия, направленного на васкуляризированную паренхиму органа. В статье представлен обзор литературы, освещающий различные методы осуществления гемостаза при выполнении резекции почки, представлены результаты крупных исследований, направленных на оценку различных способов гемостаза.

27 December 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
Ilya V. TsimafeyeuIlya V. Tsimafeyeu
Ilya V. Tsimafeyeu
VCViacheslav Chubenko
Viacheslav Chubenko
OBOlga Baklanova
Olga Baklanova
AKAlexey Kalpinskiy
Alexey Kalpinskiy
SSSufia Safina
Sufia Safina
RORashida Orlova
Rashida Orlova
Background: The RAVE-Renal study was conducted to evaluate the real-world efficacy and safety of avelumab plus axitinib as a first-line therapy for patients with metastatic renal cell carcinoma (mRCC). Methods: RAVE-Renal was a multicenter, noninterventional, ambispective study with both retrospective and prospective components. The study included adult patients with histologically confirmed mRCC, measurable disease per RECIST version 1.1, and no prior systemic therapy. Patients received avelumab (800 mg intravenously every 2 weeks) plus axitinib (5 mg orally twice daily). The primary endpoints were median progression-free survival (PFS) and objective response rate (ORR). The secondary endpoints included median OS, 1-year overall survival (OS) rate, and safety. Results: A total of 125 patients from 13 sites were enrolled, with a median follow-up of 16.1 months. The median age was 61.0 years. The study population comprised 35.3% favorable, 49% intermediate, and 15.7% poor IMDC risk patients. The median PFS was 14.9 months (95% CI, 11.72–19.08). The ORR was 44.3% (95% CI, 32.5–56.1). The clinical benefit rate was 93.4%. The 1-year OS rate was 71.2%, with the median OS not reached. Any-grade treatment-related adverse events (TRAEs) occurred in 99 (79.2%) cases, including grade ≥3 TRAEs in 24 (19.2%). Conclusions: Avelumab in combination with axitinib showed clinical benefits in a real-world setting, consistent with findings from a pivotal trial. The regimen was effective and well tolerated across various patient subgroups.

17 June 2017 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
BAB. Ya. Alekseev
B. Ya. Alekseev
AKA. S. Kalpinskiy
A. S. Kalpinskiy
ITI. A. Taraki
I. A. Taraki
AMA. A. Mukhomed’yArova
A. A. Mukhomed’yArova
KNK. М. Nyushko
K. М. Nyushko
AKAndrei Kaprin
Andrei Kaprin
Renal cell carcinoma (RCC) occupies one of the leading places in the world for morbidity among malignant neoplasms of the genitourinary system. The frequency of occurrence of bilateral RCC according to different authors is 2–6% of the total population of patients with RCC. Currently, the only effective method of treatment of bilateral RCC is surgical treatment. Patients with bilateral RCC are at high risk of dev eloping of local recurrence or progression of the disease after organ-preserving surgeries, which is why the surgeon is faced with a choice between a high risk of developing renal failure or relapse and/or progression of the disease, depending on the extent of the surgical intervention. According to the literature, in patients with bilateral RCC there was an increase in the incidence of papillary variant of RCC up to 19% and the presence of multifocal lesion. Surgical treatment of bilateral RCC is the only effective method to achieve satisfactory oncological results at a low incidence of complications. The m ost justified option for the treatment of bilateral RCC is the implementation of bilateral organ-preserving treatment, which allows achieving the optimal functional results. This article presents a clinical case of successful surgical treatment of a patient with bilateral RCC with multiple tumors.